EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study

Yu Zhang, Shuo Cao, Nan Niu iD, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang und 9 weitere

eLife · 2025

DOI: 10.7554/elife.101583 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift eLife, 2025. Verfasst von Yu Zhang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Androstadienes, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates and moderate objective response rates (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by dalpiciclib and exemestane in HR-positive, HER2-negative breast cancer.

Methods

This was a single-arm, non-controlled prospective pilot study. Treatment-naive patients with unilateral HR-positive, HER2-negative breast cancer received neoadjuvant radiotherapy (24 Gy/3 F) followed by dalpiciclib and exemestane for six cycles. The primary endpoint was the proportion of patients with residual cancer burden (RCB) score of 0-I. Key secondary endpoints included ORR, breast-conservation rate, biomarker analysis, and safety.

Results

All 12 enrolled patients completed the study treatment and surgery. Two (16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of tumor specimens showed significant increase of infiltrating T cells rather than alteration of PD-L1 positive immune cells. The most common grade 3 adverse events (AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4–5 AE or death occurred.

Conclusions

Our results suggested neoadjuvant SBRT followed by dalpiciclib and exemestane is effective and tolerable and provides novel insights for the neoadjuvant treatment of HR+/HER2- breast cancer, which may be considered as a feasible option for patients with HR-positive, HER2-negative breast cancer. Funding: None. Clinical trial number: ClinicalTrials.gov: NCT05132790

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AndrostadienesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsNeoadjuvant TherapyRadiosurgeryAdultAgedFemaleHumansMiddle AgedPilot ProjectsProspective StudiesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenTreatment OutcomePiperidinesPyridinesPyrimidines

Stichwörter der Autor:innen

CDK4/6 inhibitorSBRTbreast cancerhumanmedicineneoadjuvant

Substanzen

AndrostadienesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenPiperidinesPyridinesPyrimidinesdalpiciclibERBB2 protein, humanexemestane

Autor:innen und Institutionen

  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China.
  • Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
  • Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China.
  • Jiangsu Hengrui Pharmaceuticals, Shanghai, China.

ORCID-Profile: Nan Niu, Yongliang Yang, Caigang Liu

Zitieren

APA

Zhang, Y., Cao, S., Niu, N., Shan, H., Xue, J., Chen, G., Xu, Y., Yin, J., Liu, C., Sun, L., Jiang, X., Tang, M., Xu, Q., Jia, M., Zhang, X., Zhang, Z., Zhang, Q., Wang, J., Li, A., …, & Liu, C. (2025). Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study. eLife. https://doi.org/10.7554/elife.101583

Vancouver

Zhang Y, Cao S, Niu N, Shan H, Xue J, Chen G, et al. Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study. eLife. 2025. doi:10.7554/elife.101583

BibTeX
@article{Zhang2025,
  author = {Zhang, Yu and Cao, Shuo and Niu, Nan and Shan, Huilian and Xue, Jinqi and Chen, Guanglei and Xu, Yongqing and Yin, Jianqiao and Liu, Chao and Sun, Lisha and Jiang, Xiaofan and Tang, Meiyue and Xu, Qianshi and Jia, Mingxuan and Zhang, Xu and Zhang, Zhenyong and Zhang, Qingfu and Wang, Jianfei and Li, Ailin and Yang, Yongliang and Liu, Caigang},
  title = {Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study},
  journal = {eLife},
  year = {2025},
  doi = {10.7554/elife.101583}
}
Kostenlos starten →